Sermorelin Acetate Treatment in Growth Hormone Deficient Children: 2-Year Randomized Double-Blind Trial
Laron Z, Parks JS, Adler GK, et al.
Journal of Clinical Endocrinology & Metabolism, 1995 · n = 138
Key finding
Sermorelin increased mean height velocity from 4.2 to 8.1 cm/year and serum IGF-1 by 247% compared to baseline; sustained over 24 months.
Summary
Long-term RCT comparing sermorelin acetate twice-daily subcutaneous injection versus placebo in growth hormone-deficient children.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on Sermorelin
Sermorelin Acetate Administration Increases Mean Plasma GH Levels and Reduces Waist Circumference in Obese Men
Journal of Clinical Endocrinology & Metabolism · 2005 · Human RCT
Sermorelin Stimulates Growth Hormone Secretion in Older Adults Independent of Body Mass Index
Metabolism · 2004 · Human Pilot
Sermorelin Acetate in the Treatment of Age-Related Growth Hormone Deficiency: A Randomized Controlled Trial
Aging Clinical and Experimental Research · 2003 · Human RCT
Sermorelin Improves Insulin Secretion and Glucose Tolerance in Older Subjects with Impaired Fasting Glucose
Journal of Clinical Endocrinology & Metabolism · 2002 · Human RCT
Sermorelin Restores Bone Mineral Density in Growth Hormone-Deficient Adults: A 2-Year Randomized Trial
Journal of Clinical Endocrinology & Metabolism · 2002 · Human RCT